Clinical Trial Detail

NCT ID NCT03396211
Title Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors LSK BioPartners Inc.
Indications

Advanced Solid Tumor

breast cancer

renal cell carcinoma

lung non-small cell carcinoma

melanoma

gastric adenocarcinoma

Therapies

Nivolumab + Rivoceranib

Age Groups: senior adult

No variant requirements are available.